Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis' Certican To Get Advisory Committee Review For Heart Transplant Rejection

This article was originally published in The Pink Sheet Daily

Executive Summary

The proliferation inhibitor everolimus will be reviewed by FDA's Cardiovascular & Renal Drugs Advisory Committee on Nov. 16.

You may also be interested in...



Novartis Anticipates Diovan Pricing Will Contribute To Near-Term Growth

Pending oral iron-chelating agent Exjade could be priced at a premium compared with current first-line therapy, Novartis says during its third quarter call Oct. 18.

Novartis Anticipates Diovan Pricing Will Contribute To Near-Term Growth

Pending oral iron-chelating agent Exjade could be priced at a premium compared with current first-line therapy, Novartis says during its third quarter call Oct. 18.

Novartis' Certican Requires Further Dosing Studies, FDA "Approvable" Letter Says

The company will decide how to pursue development program for transplant agent Certican in combination with Neoral by the first week of September, Novartis says. The action letter recommends additional dosing studies of Neoral.

Related Content

Topics

UsernamePublicRestriction

Register

PS063010

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel